Page 316 - Haematologica Vol. 109 - July 2024

LETTER TO THE EDITOR
and selection of patients for risk-adapted and biomarker selected clinical trials.
Authors
Meng-Lei Zhu,1 Esther Drill,2 Erel Joffe,3 Gilles Salles,3 Alfredo Rivas Delgado,3 Andrew Zelenetz,3 Maria Lia Palomba,3 Maria Arcila1# and Ahmet Dogan1#
1Department of Pathology and Laboratory Medicine; 2Department of Epidemiology & Biostatistics and 3Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
#MA and AD contributed equally as senior authors.
Correspondence:
M.L. ZHU - zhum1@mskcc.org
https://doi.org/10.3324/haematol.2023.284565
Received: October 31, 2023. Accepted: March 1, 2024. Early view: March 14, 2024.
References
1. Ennishi D, Hsi ED, Steidl C, Scott DW. Toward a new molecular taxonomy of diffuse large B-cell lymphoma. Cancer Discov. 2020;10(9):1267-1281.
2. Boltezar L, Prevodnik VK, Perme MP, Gasljevic G, Novakovic BJ. Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma. Oncol Lett. 2018;15(5):6903-6912.
3. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
4. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-1947.
5. Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125(1):22-32.
6. Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396-1407.
7. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct
©2024 Ferrata Storti Foundation Published under a CC BY-NC license
Disclosures
No conflicts of interest to disclose.
Contributions
MZ designed the research, analyzed and interpreted the data, wrote and revised the manuscript. ED and EJ, GS, ARD analyzed and interpreted the data, and edited the manuscript. AZ and MLP collected the study cohort and edited the manuscript. MA and AD designed the research, analyzed and interpreted the data, edited the manuscript, and supervised the project.
Funding
We thank the MSK Cancer Center for their support (Grant/Core Grant: P30 CA008748). ARD was funded by a grant from Fundación Española de Hematología y Hemoterapia.
Data-sharing statement
NGS sequencing data of this study is available on https://www. cbioportal.org
pathogenic mechanisms and outcomes. Nat Med.
2018;24(5):679-690.
8. Lacy SE, Barrans SL, Beer PA, et al. Targeted sequencing in DLBCL,
molecular subtypes, and outcomes: a Haematological Malignancy
Research Network report. Blood. 2020;135(20):1759-1771. 9. Runge HFP, Lacy S, Barrans S, et al. Application of the
LymphGen classification tool to 928 clinically and genetically- characterised cases of diffuse large B cell lymphoma (DLBCL). Br J Haematol. 2021;192(1):216-220.
10. Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551-568.
11. Morin RD, Arthur SE, Hodson DJ. Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes? Br J Haematol. 2022;196(4):814-829.
12. Ptashkin RN, Ewalt MD, Jayakumaran G, et al. Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing. Nat Commun. 2023;14(1):6895.
13. Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703-713.
Haematologica | 109 July 2024
2330